Would you offer adjuvant AI + abemaciclib to a post-menopausal, node + luminal A breast cancer that did not require chemotherapy per Oncotype, yet still met criteria per monarchE?

I think it is reasonable to offer this patient adjuvant abemaciclib even though the benefit of chemotherapy is expected to be low or nil based on the 21-gene (Oncotype) recurrence score, since the overall risk of recurrence would be higher based on the anatomic stage. In fact, the RSClin scoring sys...